National Stroke Foundation

Geref (sermorelin acetate for injection)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved October 1997

Specific Treatments:

pediatric growth disorders

General Information

Serono Laboratories announced that Geref (sermorelin acetate for injection), its growth hormone releasing hormone, has received marketing clearance from the U.S. Food and Drug Administration. (FDA). Geref is indicated for growth hormone deficiency in children with growth failure and offers a new alternative of treatment.